Skip to main content
Lawrence Wiesner, DO, Orthopaedic Surgery, Vestal, NY, United Health Services Hospitals-Binghamton

LawrenceWiesnerDO

Orthopaedic Surgery • Vestal, NY

Hip & Knee Reconstructive Surgery

Director of Orthopedic Surgery

Join to view full profile

Dr. Wiesner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wiesner's full profile

Already have an account?

Education & Training

  • Peninsula Hospital Center
    Peninsula Hospital CenterResidency, Orthopaedic Surgery, 1996 - 2001
  • Lutheran Medical Center
    Lutheran Medical CenterInternship, Transitional Year, 1995 - 1996
  • NYIT College Of Osteopathic Medicine
    NYIT College Of Osteopathic MedicineClass of 1995

Certifications & Licensure

  • NY State Medical License
    NY State License 1999 - 2025
  • FL State Medical License
    FL State License 2000 - 2024
  • AOA Board of Orthopedic Surgery Orthopedic Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013

Press Mentions

  • AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement SurgeryJanuary 12th, 2022
  • AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryDecember 15th, 2021
  • AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryDecember 15th, 2021

Professional Memberships

Hospital Affiliations

Dr. Lawrence Wiesner, Dr. Lawrence Wiesner, DO, Dr. L Wiesner